News and Events


Helsinn Group and MEI Pharma Report Prolongation of Survival Results from Phase 2 Clinical Study of Pracinostat and Azacitidine in Acute Myeloid Leukemia

December 5th, 2016

Phase 2 study results presented at American Society of Hematology Annual Meeting on Saturday, December 3, 2016

Read this article

Helsinn Integrative Care Announces 510(K) FDA Clearance for Medical Device Xonrid® Gel

December 1st, 2016

Helsinn Integrative Care, Helsinn’s business unit focused on evidence-based, non-pharmaceutical cancer supportive care products, today announces that Xonrid® Gel, a topical gel for radiotherapy-induced dermatitis, already classified as a medical device in the EU, has received 510(K) FDA clearance in the US.

This now allows Xonrid® Gel to be marketed in the US for the management and relief of the burning and itching experienced by patients with radiation dermatitis.

Read this article


November 21st, 2016

On Friday November 18, 2016, 11 students received the Helsinn Advanced
Synthesis 2016/2017 Education Scholarship
of 5.000.-CHF each, for a total of 55.000 CHF


venerdì 18 novembre 2016, sono stati premiati i giovani vincitori delle 11 Borse di Studio Helsinn Advanced Synthesis per l’anno scolastico-accademico 2016/2017, per un valore totale di 55.000.-CHF.

Read this article

Helsinn Group and MEI Pharma Announce Long-Term Survival and Response Data from Phase II Clinical Study of Pracinostat in Acute Myeloid Leukemia Accepted for Oral Presentation at Upcoming American Society of Hematology Annual Meeting - Data to be present

November 3rd, 2016

Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that long-term survival and response data from a Phase II clinical study of Pracinostat and azacitidine in older patients with acute myeloid leukemia have been selected for oral presentation at the upcoming American Society of Hematology (ASH) Annual Meeting in San Diego on December 3-6, 2016.

Read this article

Swissmedic approves ALOXI® for use in the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Children in Switzerland

October 25th, 2016

Swiss approval of ALOXI® for paediatric use follows EMA approval in February 2015 and FDA approval in May 2014

Read this article


October 10th, 2016

Helsinn Group creates new investment fund in 40th anniversary year

The new fund will focus on supporting early-stage investment opportunities in areas of high unmet patient need

Read this article

View all news articles


Helsinn at ESMO 2017 in Madrid

September 8th, 2017

Madrid, Spain 8-12 September 2017

Event information

Helsinn will attend at ASCO 2017

June 2nd, 2017

The "2017 ASCO Annual Meeting -Making a Difference in Cancer Care" will take place in Chicago, Illinois, on June 2-6 2017

Event information

Helsinn Attendance at J.P. Morgan Annual Healthcare Conference

January 9th, 2017

Helsinn is at the 35th Annual JP Morgan Healthcare Conference taking place from January 9 to 13, 2017 in San Francisco, CA.

Event information

View all events